http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108379250-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f1649e51d42002ff75e3dc3dc8ef653 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 |
| filingDate | 2018-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69c8ae7feeb1286822c295aa9eb4d062 |
| publicationDate | 2018-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108379250-A |
| titleOfInvention | Chloranthalactone A is used as the biomedical uses of 1 inhibitor of indoleamine 2,3-dioxygenase |
| abstract | The invention discloses chloranthalactone A to be used as indoleamine 2, the biomedical uses of 3 dioxygenase, 1 inhibitor.It is a discovery of the invention that chloranthalactone A, chloranthalactone C, chloranthalactone D, chloranthalactone E and chloranthalactone F are indoleamine 2, effective inhibitor of 3 dioxygenases 1 (IDO1).Numerous studies show that the unconventionality expression of IDO1 is related with tumour cell escape immune system, therefore IDO1 is inhibited to be expected to become a kind of novel tumor therapeutic strategy.Currently, indoximod, epacadostat and NLG919 are the IDO1 inhibitor in clinical investigation phase, in addition there are multiple inhibitor to be in the biological activity test stage.IDO1 inhibitor has a extensive future. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111035623-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111035623-A |
| priorityDate | 2018-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 196.